Chang SL

Oncology Program, CHU de Québec-Université Laval Research Center, Quebec, QC G1S 4L8, Canada.

8 papers · ORCID

ArticlePsilocybin

Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation.

Dorval M, Audet-Croteau V, Chang SL +6

Europe PMC2026
ArticlePsilocybin

Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.

Plourde L, Chang SL, Nguyen O +5

Europe PMC2026
ArticlePsychedelics

End of life distress as an economic issue: The case for psychedelic-assisted therapy - ERRATUM.

Dorval M, Audet-Croteau V, Chang SL +2

Europe PMC2026
ArticlePsychedelics

End of life distress as an economic issue: The case for psychedelic-assisted therapy.

Dorval M, Audet-Croteau V, Chang SL +2

Europe PMC2026
ArticlePsilocybin

Supporting Meaningful Choices: A Decision Aid for Individuals Facing Existential Distress and Considering Psilocybin-Assisted Therapy.

Bélanger A, Chang SL, Stephan JF +7

Europe PMC2025
ArticlePsilocybin

Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians' Concerns.

Cheung K, Brodie M, Chang SL +7

Europe PMC2025
ArticlePsilocybin

Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care.

Dorval M, Chang SL, Farzin H +10

Europe PMC2025
ArticlePsilocybin

Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey.

Plourde L, Chang SL, Farzin H +11

Europe PMC2024